News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,770 Results
Type
Article (14273)
Company Profile (281)
Press Release (254216)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79555)
Career Advice (153)
Deals (13232)
Drug Delivery (35)
Drug Development (50475)
Employer Resources (31)
FDA (5728)
Job Trends (5138)
News (144478)
Policy (10033)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21682)
ALS (68)
Alzheimer's disease (850)
Antibody-drug conjugate (ADC) (108)
Approvals (5753)
Artificial intelligence (132)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1515)
Cardiovascular disease (120)
Career advice (134)
Career pathing (2)
CAR-T (121)
Cell therapy (337)
Cervical cancer (9)
Clinical research (41165)
Collaboration (557)
Compensation (275)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (171)
Cystic fibrosis (77)
Data (1592)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1302)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30071)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48761)
Executive appointments (471)
FDA (6492)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (509)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (370)
Government (1084)
Grass and pollen (2)
Guidances (66)
Healthcare (6595)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7280)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (214)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (147)
MASH (59)
Medical device (2602)
Medtech (2603)
Mergers & acquisitions (6290)
Metabolic disorders (402)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1269)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (22)
Obesity (197)
Opinion (102)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (121)
Partnered (8)
Patents (135)
Patient recruitment (82)
Peanut (35)
People (25683)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14540)
Phase II (19157)
Phase III (12094)
Pipeline (915)
Policy (48)
Postmarket research (852)
Preclinical (6155)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (296)
Real estate (1419)
Recruiting (12)
Regulatory (8675)
Reports (16)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (62)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (216)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Last 7 days (555)
Last 30 days (1695)
Last 365 days (19249)
2025 (6915)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7429)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17343)
Australia (2941)
California (4036)
Canada (1170)
China (372)
Colorado (152)
Connecticut (154)
Delaware (109)
Europe (37360)
Florida (491)
Georgia (121)
Idaho (16)
Illinois (238)
India (10)
Indiana (94)
Iowa (2)
Japan (78)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (492)
Massachusetts (3209)
Michigan (72)
Minnesota (150)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1001)
New Mexico (12)
New York (1081)
North Carolina (567)
North Dakota (5)
Northern California (1796)
Ohio (114)
Oklahoma (9)
Oregon (21)
Pennsylvania (762)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1553)
Tennessee (25)
Texas (468)
United States (13781)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (359)
Wisconsin (16)
268,770 Results for "addex therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
April 24, 2025
·
3 min read
Press Releases
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
April 17, 2025
·
3 min read
Press Releases
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
April 25, 2025
·
8 min read
Press Releases
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
April 30, 2025
·
5 min read
Press Releases
Addex to Present at the 2025 Swiss Equities Baader Conference
January 8, 2025
·
3 min read
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, reported its Q1 2024 financial results and provided a corporate update.
June 6, 2024
·
7 min read
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Addex Therapeutics announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
April 3, 2024
·
7 min read
Addex to Present at Bio€quity Europe 2024
Addex Therapeutics announced that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
May 8, 2024
·
3 min read
Business
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
April 18, 2024
·
7 min read
Addex Convenes Annual General Meeting 2024
Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva.
June 5, 2024
·
5 min read
1 of 26,877
Next
